The pharmacokinetics of ampicillin-sulbactam in elderly subjects (65 to 85 years; group 3, n = 8), compared with those in middle-aged (41 to 64 years; group 2, n = 8) and younger (20 to 40 years; group 1, n = 8) subjects, were investigated. A single 2-g dose of anpicillin combined with 1 g of sulbactam in 60 ml of intravenous solution was administered to each subject over a 30-min period. Blood and urine samples were taken at baseline and serially over an 8.5-h period foliowing the infusion. Ampicillin and sulbactam concentrations were assayed by high-performance Liquid chromatography on a reversed-phase C-8 column. The mean levels in serum of both ampicilin and sulbactam were significantly higher for samples from group 3: for ampillin from 1 through 8.5 h, and for sulbactam for the same time interval except at 5.5 h (P ' 0.05). The mean urinary excretion of both ampicillin and sulbactam was lowest, and urinary concentrations were highest in group 3. The areas under the serum drug concentration-time curve, the half-lives, and the maimum concentrations in serum were greatest, while the total clearance was lowest, for group 3 for both ampilin and sulbactam. These results are consistent with a prolongation of antimicrobial activity of ampicilli-sulbactam in the elderly compared with that in younger subjects.
Demographic trends over the past 50 years reveal that the elderly (over age 65) are a rapidly growing segment of the population (16) . Physiologic changes in the elderly compared with younger populations have been noted (9) . Age-related diferences in absorption, excretion, metabolism, and distriIlution make it necessary to study new agents in elderly populations. In the elderly, there is an increase in body fat, a decrease in body water, and an age-related decline in renal function. Other factors that may impact on the pharmacokinetics of antimicrobial agents include serum albumin and protein binding. A guideline for the study of drugs in the elderly has recently been released (3) .
Prior studies of the pharmacokinetics of antibiotics in the elderly have been recently reviewed in two publications (8, 11) . 4alysis of the data for beta-lactam antibiotics reveals that, id the elderly, the maximum concentrations in serum, (CX,~), area under the concentration-time curve (AUC), and half-life (tQ122) are increased, whereas total clearance (CLT) and renal clearance (CLR) are decreased, compared with what is observed for younger populations.
Ampicillin-sulbactam is an antimicrobial agent that has potential for use in elderly populations in the treatment of intraabdominal, pelvic, skin/soft tissue, and pulmonary infections (1) . Sulbactam is a beta-lactam agent that acts as an irreversible inhibitor of beta-lactamase activity by combining with the enzyme and rendering it inactive. The pharmacokinetics of ampicillin-sulbactam in the elderly have not been extensively studied (5, 14) . In this study, we examined the pharmacokinetic parameters of ampicillin-sulbactam in three healthy groups: elderly, middle-aged, and younger subjects. * serum matrix after the precipitation of serum proteins with acetonitrile. The isolate was analyzed by HPLC on a reversed-phase C-8 column. The mobile phase consisted of a mixture of trisodium tetrabutylammonium phosphate and acetonitrile in water at pH 6.8. The column effluent entered a postcolumn reactor system, where it was mixed with two solutions (1.5 N NaOH in methanol-water and a dilute solution of mercuric chloride and EDTA in methanol-water).
A postcolumn degradation reaction occurred in the mixing coil of the reactor system. Detection of the degraded sulbactam and ampicillin moieties was by UV absorbance at 290 nm. Specificity. On 3 consecutive days, a sample of pooled control serum was extracted and analyzed according to the method presented above. The chromatograms were examined for potentially interfering peaks in or around the retention times of sulbactam, ampicillin, and cefazolin. The pooled control serum chromatograms were found to have minor peaks near the retention times of sulbactam and ampicillin. However, those peaks did not appear to significantly interfere with the analysis of either moiety.
Linearity. On 3 consecutive days, the HPLC system response (peak height ratios) to sulbactam and ampicillin was tested; for sulbactam, the response was found to be linear in the range of 0.5 to greater than 50 jig/ml, and for ampicillin it was linear in the range of 1 to 100 ,ug/ml. On the fourth day, an extended calibration curve was prepared. The HPLC system response to sulbactam and ampicillin was against tested; for sulbactam, it was found to be linear in the range of 0.5 to greater than 75 jig/ml, and for ampicillin it was linear in the range of 1 to greater than 150 ,ug/ml. The peak height ratios of sulbactam/internal standard and ampicillin/internal standard were determined. Calibration curves were prepared on the basis of peak height ratios versus the concentrations of sulbactam and ampicillin in the serum matrix. A linear regression analysis of the data was used to calculate slope, intercept, and correlation coefficient for both sulbactam and ampicillin.
Accuracy and precision of the assay. The accuracy and precision (short term) of the assay were evaluated by preparing extracts of pooled control serum fortified to contain standard low-spike, mid-spike, and high-spike concentrations of sulbactam and ampicillin. For sulbactam, the concentrations (in micrograms per milliliter) and relative standard deviations were as follows: low spike, 0.51 and 21.5%; mid spike, 20.4 and 1.7%; high spike, 51.0 and 1.1%. For ampicillin,athe concentrations (same units) and relative standard deviations were as follows: low spike, 1.0 and 6.0%; mid spike, 39.9 and 3.5%; high spike, 99.7 and 3.6%. Each sample wa analyzed in duplicate on 3 consecutive days. Average concentrations of each moiety and relative standard deviations were then calculated for each sample. The average low-spike, mid-spike, and high-spike concentrations of sulbactam and ampicillin were found to be 0.65 and 1.4
,ug/ml, 20.5 and 40.5 p.g/ml, and 53.0 and 106 ,ug/ml, respectively. Although the average measured concentrations for sulbactam and ampicillin in the low and high spikes were slightly greater than expected, they were considered acceptable for these purposes. Data analysis. The AUC for ampicillin and sulbactam from time 0 to 12.0 h (AUCO12) and from 0 to infinity (AUC), the Cmax, and the time to reach maximum drug concentration in serum (Tmax) were determined for each subject. AUCO_12
was calculated by the trapezoidal method. AUC was the sum of AUCO12 and the residual area from 12.0 h to infinity; the residual area was calculated as the estimated concentration at 12.0 h divided by the elimination phase rate constant (beta). Beta for each subject was estimated from the slope of the log-linear segment of the serum drug concentration-time curve. Half-lives were calculated as iteratively reweighted least-squares estimates from nonlinear regressions by using a linear, two-compartment model in PCNONLIN, the halflives, and their means and standard deviations (Table 3) . Total body clearance (CLT) was determined as dose per AUC, and volume of distribution (V) was calculated from the formula total body clearance/beta. The total amount of ampicillin and sulbactam recovered from urine from 0 to 8.5 h was also determined. Renal clearance was calculated as Dex/AUC, where Dex is the amount of drug excreted unchanged in the urine. Bioequivalence of ampicillin and sulbactam were compared following the administration of each drug in combination with the other drug. Bioequivalence was tested by using the two one-sided tests procedure for AUC and Cmax.
Statistical analysis. Differences in patient characteristics and pharmacokinetic parameters were compared across the three age groups by using two-tailed tests of significance. Analysis of variance was used to measure differences between groups. Significance was defined as P _ 0.05. All statistical analyses were performed by using statistical package social services/PC+, version 3.1.
RESULTS
The demographic data for the three subject groups is shown in Table 1 . There were no significant differences between the three age groups in mean height, weight, albumin, or serum creatinine. The mean calculated creatinine clearance (CLCR) (2) was least for the elderly group 3 (P ' 0.0003). Mean creatinine or calculated clearance was significantly different between groups 1 and 3 (P _ 0.01) and between groups 2 and 3 (P ' 0.01).
The mean levels in serum for both ampicillin and sulbactam are shown on Table 2 . For time periods 0, 0.25, and 0.50 h, there were no differences among the three groups for ampicillin and sulbactam. Throughout the rest of the serial determinations, the levels for group 3 for each time period for ampicillin were greater than for groups 1 and 2 (P _ 0.01 
(P = NS).
In contrast, the mean urinary concentration of ampicillin was highest for group 3 (177.6 ,ug/ml, versus 91.1 ,ug/ml for group 2 and 44.3 ,ug/ml for group 1 [P = NS]). The urinary concentration of sulbactam was highest for group 3 (103.7 ,ug/ml, versus 56.9 ,ug/ml for group 2 and 30.0 ,ug/ml for group 1 
[P = NS]).
Pharmacokinetic analysis. The tl/2,3 for ampicillin was greatest for group 3 (1.35 h) and decreased from group 2 to group 1 (P = 0.0002) ( Table 3 ). For sulbactam, the results were similar: the highest t1/2, (1.58 h) was for group 3 (P = 0.0001). The AUC for ampicillin was greatest for group 3 (182.2 pug/ml ± 57.8 ,ug/ml [standard deviation]) and lowest for group 1 (P ' 0.004). The AUC for both ampicillin and sulbactam was significantly different between groups 1 and 3 (ampicillin, P ' 0.05; sulbactam, P _ 0.01) and between groups 2 and 3 (ampicillin, P _ 0.05; sulbactam, P _ 0.01). The Cmax was greatest for ampicillin (112.4 pug/ml + 34.3 ,ug/ml) for group 3 (P = NS). For sulbactam, the Cmax was also greatest for group 3 (59.1 ,ug/ml 19.9 ,uglml) (P = NS). The CLT of ampicillin and sulbactam varied inversely with age. The CLT of ampicillin and sulbactam was significantly different between groups 1 and 3 (P -0.01) and between groups 2 and 3 (P ' 0.05). CLR of both ampicillin and sulbactam was significantly different between groups 1 and 3 (P ' 0.01). Group 3 had the lowest V for ampicillin and sulbactam, but it was not statistically different from that of the other age groups.
Correlations Adverse effects. There were two patients with adverse effects. Vomiting and a migraine headache occurred in one volunteer, and the other had pain at the site of the drug infusion. The symptoms were reversible and of short duration. There were no changes in laboratory parameters following drug administration in any of the three groups.
DISCUSSION
Analysis of the demographic data revealed no differences among the three groups; albumin levels were lower among the older patients, but not significantly. It has been shown that healthy elderly volunteers may have lower serum albumin levels than members of a younger age group (10) . While this may affect the level of free drug with those agents which are highly protein bound, we would not expect any changes with either ampicillin, which is 18% protein bound, or with sulbactam, which is 38% protein bound (15) . The calculated CLCR was significantly lower for group 3. This is not unexpected, since renal function is known to decrease with age (11, 14) .
In our study, the mean levels in serum of both ampicillin This is similar to the findings of another reported study (14) . and sulbactam (P = 0.0001) and the Cmax were also greatest for group 3 (P = NS). Our data is comparable to that previously reported (14) ; however, in that study, the t1/2 for the subjects was greater. This observation may be explained by the greater age of their group and age-associated decline in renal function. In both studies, V was not different between the young and old volunteers. However, in our study, V was lowest for group 3 for both ampicillin and sulbactam. In a prior study on cefoperazone in elderly volunteers, similar findings were observed (9) . For watersoluble drugs (polar compounds), this is not unexpected, since in the elderly, a decreased lean body mass coupled with a decrease in total body water is usually associated with a decrease in V (11). Our data reveal a prolongation of antimicrobial activity in elderly subjects compared with younger subjects, as manifested by an increase in Cmax, higher sustained concentrations throughout the dosing intervals, increased AUC, and decreased CLT. This is consistent with prior studies that have correlated these pharmacokinetic parameters with antibacterial activity (4) . Presumably, these changes would be further magnified in infected elderly patients. Studies with ceftazidime and cefotaxime have revealed similar changes (6, 7, 12) .
Prior investigations have suggested that middle-aged adults should be studied (14) to determine the impact of age and CLCR on pharmacokinetic parameters. While we noted differences in CLCR between the elderly group and both younger adult groups, there were no differences in CLCR between middle-aged and younger adults (P = NS). Similarly, our study also revealed no differences between middleaged and younger adults for any of the pharmacokinetic parameters examined. This suggests that the pharmacokinetic parameters observed are a function of CLCR, not of age. However, further studies with elderly volunteers with higher CLCR values are needed to confirm this.
Analysis of covariance revealed that, when creatinine clearance was used as the covariate, the age group did not add any significant effect for either sulbactam clearance (F(1 19) = 17.93, P = 0.001) or ampicillin clearance (F(1 19) 
